Details of the Drug-Related molecule(s) Interaction Atlas

Sphinx Drug Info

SPHINX; AC1NI3K3; SCHEMBL15648757; US9695160, SPHINX; BDBM221070; ZINC6790230; AKOS001099848; MCULE-7133870197; 5-methyl-N-[2-morpholin-4-yl-5-(trifluoromethyl)phenyl]furan-2-carboxamide; 5-methyl-N-(2-morpholino-5-(trifluoromethyl)phenyl)furan-2-carboxamide; 5-methyl-N-[2-(morpholin-4-yl)-5-(trifluoromethyl)phenyl]furan-2-carboxamide; 848057-98-7

Cross-matching ID

PubChem CID

4799939

TTD Drug ID

DMJF6S0

General Information of Drug (ID: DMJF6S0)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting SRSF protein kinase 1 (SRPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ZINC959121	DMR0F4H	N. A.	N. A.	Patented	[1]
SPHINX scaffold, 3	DM8XJTH	N. A.	N. A.	Patented	[1]
SPHINX31	DMYZQKC	Wet age-related macular degeneration	9B78.3Z	Preclinical	[2]
PMID15925511C13	DMHY95J	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Piperazine derivatives for treating disorders. US9695160.
2	Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018 May;17(5):353-377.
3	Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives. Bioorg Med Chem Lett. 2005 Jul 1;15(13):3241-6.